IBI322
Multiple cancers
Phase 1/2Active
Key Facts
About Innovent Biologics
Innovent Biologics is one of China's premier biotechnology companies, established in 2011 and publicly traded on the Hong Kong Stock Exchange. The company specializes in developing innovative biologics for oncology, autoimmune, and metabolic diseases, with a strong focus on monoclonal antibodies and bispecific antibodies. Innovent has successfully commercialized multiple products in China and has strategic partnerships with global pharmaceutical companies including Eli Lilly and Roche.
View full company profileTherapeutic Areas
Other Multiple cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Tecentriq (atezolizumab) | Chugai Pharmaceutical | Approved |
| Avastin (bevacizumab) | Chugai Pharmaceutical | Approved |
| Sintilimab (IBI308) | Innovent Biologics | Approved |
| Bevacizumab biosimilar (IBI305) | Innovent Biologics | Approved |